<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="4764">
  <stage>Registered</stage>
  <submitdate>22/12/2014</submitdate>
  <approvaldate>22/12/2014</approvaldate>
  <nctid>NCT02325830</nctid>
  <trial_identification>
    <studytitle>CARILLON Mitral Contour System® for Reducing Functional Mitral Regurgitation</studytitle>
    <scientifictitle>The REDUCE FMR Trial: Safety and Efficacy of the CARILLON Mitral Contour System® in Reducing Functional Mitral Regurgitation (FMR) Associated With Heart Failure</scientifictitle>
    <utrn />
    <trialacronym>REDUCE FMR</trialacronym>
    <secondaryid>CVP 1627-01</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Mitral Valve Insufficiency</healthcondition>
    <healthcondition>Heart Failure</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Coronary heart disease</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Other cardiovascular diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: devices - CARILLON Mitral Contour System

Experimental: Treatment Group - Implantation of the CARILLON Mitral Contour System

No Intervention: Control Group - Optimized stable medical therapy


Treatment: devices: CARILLON Mitral Contour System
Percutaneous mitral valve repair

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: devices</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Change in regurgitant volume associated with the CARILLON device relative to the Control population</outcome>
      <timepoint>12 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Document the difference in the rate of major adverse events between Treatment (CARILLON) and Control groups</outcome>
      <timepoint>30 days and 12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Assess rate of heart failure hospitalizations between Treatment (CARILLON) and Control groups</outcome>
      <timepoint>12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Assess the change in six-minute walk distance between Treatment (CARILLON) and Control groups</outcome>
      <timepoint>12 Months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Assess the change in left ventricular volumes between Treatment (CARILLON) and Control groups</outcome>
      <timepoint>12 Months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Diagnosis of dilated ischemic or non-ischemic cardiomyopathy

          -  Functional Mitral Regurgitation: 2+ (Moderate), 3+ (Moderate/Severe), or 4+ (Severe)

          -  New York Heart Association (NYHA) II, III, or IV

          -  Six Minute Walk distance of at least 150 meters and no farther than 450 meters

          -  Left Ventricular Ejection Fraction = 50 %

          -  LV end diastolic dimension (LVEDD) &gt;55mm or LVEDD/Body Surface Area (BSA) &gt; 3.0cm/m2

          -  Stable heart failure medication regimen for at least three (3) months prior to index
             procedure</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>85</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Hospitalization in past three (3) months due to myocardial infarction, coronary artery
             bypass graft surgery, and/or unstable angina

          -  Hospitalization in the past 30 days for coronary angioplasty or stent placement

          -  Subjects expected to require any cardiac surgery within one (1) year

          -  Subjects expected to require any percutaneous coronary intervention within 30 days of
             enrollment

          -  Pre-existing device (e.g., pacing lead) in coronary sinus (CS) / great cardiac vein
             (GCV), or anticipated need for CRT within twelve (12) months

          -  Presence of a coronary artery stent under the CS / GCV in the implant target zone

          -  Presence of left atrial appendage (LAA) clot.

          -  Presence of primary renal dysfunction or significantly compromised renal function as
             reflected by a serum creatinine &gt; 2.2 mg/dL OR eGFR &lt; 30 ml/min

          -  Inability to undertake a six-minute walk test due to physical restrictions/limitations

          -  Chronic severe pathology limiting survival to less than 12-months</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3>The people assessing the outcomes</masking3>
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate />
    <actualstartdate>1/03/2015</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>180</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/12/2018</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,SA,VIC</recruitmentstate>
    <hospital>Royal North Shore Hospital - St. Leonards</hospital>
    <hospital>Royal Prince Alfred - Sydney</hospital>
    <hospital>Flinders Medical Centre - Adelaide</hospital>
    <hospital>Monash Health - Clayton</hospital>
    <hospital>Alfred Health - Prahran</hospital>
    <postcode>2065 - St. Leonards</postcode>
    <postcode> - Sydney</postcode>
    <postcode>5042 - Adelaide</postcode>
    <postcode>3168 - Clayton</postcode>
    <postcode>3181 - Prahran</postcode>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Olomouc</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Prague</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Auvergne</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Caen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Montpellier</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Rouen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Toulouse</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>North Rhine-Westphalia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Berlin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Bochum</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Frankfurt am Main</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Frankfurt</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Freiburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Lübeck</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Recklinghausen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Maastricht</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Grafton</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Poznan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Middlesex</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Yorkshire</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Newcastle upon Tyne</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Cardiac Dimensions Pty Ltd</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Menzies Institute for Medical Research</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The objective of this prospective, multi-center, randomized, double-blind trial is to assess
      the safety and efficacy of the CARILLON Mitral Contour System in treating functional mitral
      regurgitation (FMR) associated with heart failure, compared to a randomized Control group
      which is medically managed according to heart failure guidelines.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02325830</trialwebsite>
    <publication>Schofer J, Siminiak T, Haude M, Herrman JP, Vainer J, Wu JC, Levy WC, Mauri L, Feldman T, Kwong RY, Kaye DM, Duffy SJ, Tübler T, Degen H, Brandt MC, Van Bibber R, Goldberg S, Reuter DG, Hoppe UC. Percutaneous mitral annuloplasty for functional mitral regurgitation: results of the CARILLON Mitral Annuloplasty Device European Union Study. Circulation. 2009 Jul 28;120(4):326-33. doi: 10.1161/CIRCULATIONAHA.109.849885. Epub 2009 Jul 13.
Siminiak T, Wu JC, Haude M, Hoppe UC, Sadowski J, Lipiecki J, Fajadet J, Shah AM, Feldman T, Kaye DM, Goldberg SL, Levy WC, Solomon SD, Reuter DG. Treatment of functional mitral regurgitation by percutaneous annuloplasty: results of the TITAN Trial. Eur J Heart Fail. 2012 Aug;14(8):931-8. doi: 10.1093/eurjhf/hfs076. Epub 2012 May 21.
Siminiak T, Hoppe UC, Schofer J, Haude M, Herrman JP, Vainer J, Firek L, Reuter DG, Goldberg SL, Van Bibber R. Effectiveness and safety of percutaneous coronary sinus-based mitral valve repair in patients with dilated cardiomyopathy (from the AMADEUS trial). Am J Cardiol. 2009 Aug 15;104(4):565-70. doi: 10.1016/j.amjcard.2009.04.021. Epub 2009 May 29.
</publication>
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Horst Sievert, MD</name>
      <address>Cardio Vascular Center</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Nawzer Mehta, Ph.D.</name>
      <address />
      <phone>+1 425 605 5922</phone>
      <fax />
      <email>nmehta@cardiacdimensions.com</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>